Argenica Therapeutics Ltd Ordinary Shares AGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.56
- Day Range
- A$0.55–0.57
- 52-Week Range
- A$0.30–0.75
- Bid/Ask
- A$0.55 / A$0.57
- Market Cap
- A$69.39 Mil
- Volume/Avg
- 119,835 / 149,037
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- https://www.argenica.com.au
Valuation
|
Metric
|
AGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AGN
|
|---|---|
Quick Ratio | 4.23 |
Current Ratio | 4.25 |
Interest Coverage | — |
Quick Ratio
AGN
Profitability
|
Metric
|
AGN
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gppqqpxht | Ghkj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Drvyxlr | Bxrcz | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Njxjbtcyt | Xdrgrm | $97.8 Bil | |
MRNA
| Moderna Inc | Vwpldwc | Tygrf | $41.3 Bil | |
ARGX
| argenx SE ADR | Knwpnnt | Mgj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Zmygllfv | Bqgwm | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tlyylypt | Pkzcg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lkcwhkhs | Gqdgd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gbdtxvttq | Hxcsndz | $12.5 Bil | |
INCY
| Incyte Corp | Dfcdcrgrk | Wxkfsz | $11.6 Bil |